ASH 2021

Part I: Pola-R-CHP - possible new standard in 1st line?

Prevention of CNS relapse after R-CHOP

pola-R-CHP vs. R-CHOP: a new standard?

HD-MTX does not lower SCNS rates in high-risk patients

Tisa-cel - new CAR-T option for R/R aNHL

Axi-cel - new standard for r/r LBCL patients?

Axi Cel: un nuovo standard nel DLBCL recidivato o…

La prevenzione della recidiva a carico del sistema…

pola-R-CHP vs. R-CHOP: Neuer Standard?

Part II: The white elephant in the room - BTKi

Next generation BTKI Pirtobrutinib

Glofitamab SUD as monotherapy after Gpt induced high…

HiDAC-containing induction before ASCT substantially…

Pirtobrutinib shows promising efficacy and safety in…

Focus on maintenance is critical in MCL

Pirtobrutinib - promising agent moving forward

Low-dose lenalidomide added to rituximab maintenance in…

Maintenance with Rituximab-Lenalidomid (R2)

Rituximab-Lenalidomid Erhaltungstherapie (R2)

Añadir lenalidomida a dosis bajas a rituximab en el…

Eficacia y seguridad de brexu-cel en pacientes con LCM…

Ruolo del mantenimento con R2 nel linfoma mantellare

Pirtobrutinib es eficaz y seguro en pacientes muy…

Pirtobrutinib: Neuer, nicht-kovalenter BTKi

Part I: CAR-T cells on the way

Novel immunotherapy approaches to R/R follicular…

First-line options and RM

MRD monitoring in follicular lymphoma is extremely…

Rituximab-Erhaltung nach ICT bleibt Standard

Ruolo del monitoraggio della malattia minima residua…

Part II: More data to wait for

BTKi as new option for untreated CLL/SLL patients

NDMM: On the way to cure?

The immunotherapy tsunami continues - bispecific…

The immunotherapy tsunami continues - CAR-T cells

Quadruple regimens for NDMM

PFS separation in the Griffin trial

No benefit for elotuzumab in NDMM

Triplet therapie in elderly patients

Quadruple therapy - the treatment of choice in NDMM

Positive results for high-risk myeloma from the UK

Isatuximab + RVd erfogreich, Elotuzumab nicht

Quadrupletts Dara-VTd bzw. Dara-RCd erste Optionen bei…

PFS separation in the Griffin trial

New bispecific antibodies and CAR-T cells for RRMM…

talquetamab & cevostamab: bispecific antibodies beyond…

Elranatamab - a new bispecific antibody in RRMM

TAK-573 - a really new mechanism of treatment in…

Update on bispecific antibody teclistamab

KRd consolidation reverses PET positivity in 1/3 of the…

cilta-cel highly effective in heavily pretreated…

cilta-cel: early, deep and durable responses in heavily…

Not another BCMA drug

Is CAR-T cell treatment better in heavly pretreated…

New bispecific antibodies and CAR-T cells for RRMM…

Bispezifischer Antikörper Teclistamab beim r/r MM

TAK-573 - a really new mechanism of treatment in…

cilta-cel: frühes, tiefes, lang anhaltendes Ansprechen…

KRd consolidation reverses PET-positivity in 1/3 of the…

Talquetamab und Cevostamab: Neue bispezifische Ak…

CAR-T oder bispezifische MoAk in der Rezidivtherapie -…

Myeloma precursor disease 2021

New reference values for light chains in multiple…

Prävalenz und Risikostratifikation beim SMM

New reference values for light chains in multiple…